Phaseline

Targets › HYAL1

HYAL1 (Hyaluronidase-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Jun 2027.

May have a role in promoting tumor progression. May block the TGFB1-enhanced cell growth. (UniProt, Q12794)

Open in Phaseline: the race on HYAL1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johns Hopkins UniversityHyaluronidase (HYLENEX recombinant)
Hyaluronidase enzyme that hydrolyzes hyaluronic acid in the extracellular matrix to reduce
HYAL1Phase 2Muscle SpasticityJun 2027

Conditions

Muscle Spasticity (1)

Modalities

protein or peptide (1)

Companies

Johns Hopkins University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.